Skip to main content

Summary

for people ages 18–55 (full criteria)
healthy people welcome
at San Francisco, California
study started
estimated completion:

Description

Summary

This study will investigate the effects of oxytocin on alcohol-related behaviors, social abilities, and physiological startle responses in healthy individuals and patients with posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) using a randomized, placebo-controlled, dose-tiered, between-subject study design. Specifically, the investigators will determine if intranasal administration of a single dose of the pro-social neuropeptide oxytocin decreases alcohol-related approach bias and cravings, enhances social abilities, and decreases physiological hyperactivity. The investigators will also determine the optimal dose to achieve these effects and will explore psychosocial predictors of responses to oxytocin. The proposed work has the potential to yield a novel pharmacological treatment for AUD and PTSD, both leading causes of disability in the US Military for which currently available treatments are inadequate.

Official Title

The Effects of Oxytocin on Social Ability, Alcohol Approach Bias, and Startle Hyperreactivity in Veterans With Alcohol Use Disorder and Post Traumatic Stress Disorder

Keywords

Stress Disorders, Post-Traumatic Alcoholism oxytocin PTSD Alcohol Use Disorder social cognition craving fear-potentiated startle Stress Disorders, Traumatic

Eligibility

You can join if…

Open to people ages 18–55

  1. Ages 18 to 55 (inclusive)
  2. Current DSM-V diagnosis of PTSD
  3. Current (past month) DSM-V diagnosis of a moderate to severe Alcohol Use Disorder

You CAN'T join if...

  1. Psychotic disorders, such as bipolar disorder, dementia, or other psychiatric disorders judged to be unstable.
  2. Subjects known to have clinically significant unstable medical conditions, including but not limited to clinically significant renal disease and/or impaired renal function as defined by clinically significant elevation of blood urea nitrogen (BUN) or creatinine or an estimated creatinine clearance of < 60 mL/min, AST and/or ALT >5 times the upper limit of the normal range and/or an increased serum bilirubin >2 times the upper limit of normal.
  3. Current medications for alcohol dependence (disulfiram, naltrexone, or acamprosate) or use in the past week.
  4. Needing acute medical detoxification from alcohol based on a score of 12 or more on the Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-AD);
  5. Subjects who are legally mandated to participate in an alcohol treatment program.
  6. Subjects who have had a suicide attempt in the past 6 months or suicidal ideation in the 90 days prior to enrollment.
  7. Subjects with seizure disorders that require anticonvulsant medications
  8. Positive urine pregnancy test, women meeting DSM-V criteria for premenstrual dysphoric disorder or with diseases likely to influence hormonal or neuroendocrine status
  9. Sensitivity to preservatives (in particular E 216, E 218 and chlorobutanol hemihydrate)
  10. . Nasal obstruction, discharge, or bleeding
  11. . Taking antipsychotics or mood stabilizers, testosterone or estrogen/progesterone supplement, or 5HT1a agonists/antagonists, as these agents can alter oxytocin levels

Location

  • San Francisco Veterans Affairs Medical Center accepting new patients
    San Francisco, California, 94121, United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT02469259
Phase
Phase 1
Lead Scientist
Josh D Woolley
Study Type
Interventional
Last Updated
May 2016
I’m interested in this study!